AU2008345689B2 - BMP mutants with decreased susceptibility to Noggin - Google Patents

BMP mutants with decreased susceptibility to Noggin Download PDF

Info

Publication number
AU2008345689B2
AU2008345689B2 AU2008345689A AU2008345689A AU2008345689B2 AU 2008345689 B2 AU2008345689 B2 AU 2008345689B2 AU 2008345689 A AU2008345689 A AU 2008345689A AU 2008345689 A AU2008345689 A AU 2008345689A AU 2008345689 B2 AU2008345689 B2 AU 2008345689B2
Authority
AU
Australia
Prior art keywords
bmp
amino acid
protein
modified
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008345689A
Other languages
English (en)
Other versions
AU2008345689A1 (en
Inventor
Moulay Hicham Alaoui-Ismaili
Kening Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of AU2008345689A1 publication Critical patent/AU2008345689A1/en
Application granted granted Critical
Publication of AU2008345689B2 publication Critical patent/AU2008345689B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2008345689A 2007-12-21 2008-12-19 BMP mutants with decreased susceptibility to Noggin Ceased AU2008345689B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US875407P 2007-12-21 2007-12-21
US61/008,754 2007-12-21
PCT/US2008/087720 WO2009086131A1 (en) 2007-12-21 2008-12-19 Bmp mutants with decreased susceptibility to noggin

Publications (2)

Publication Number Publication Date
AU2008345689A1 AU2008345689A1 (en) 2009-07-09
AU2008345689B2 true AU2008345689B2 (en) 2013-04-18

Family

ID=40424155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008345689A Ceased AU2008345689B2 (en) 2007-12-21 2008-12-19 BMP mutants with decreased susceptibility to Noggin

Country Status (6)

Country Link
US (2) US20110039773A1 (enExample)
EP (1) EP2222696A1 (enExample)
JP (2) JP5529754B2 (enExample)
AU (1) AU2008345689B2 (enExample)
CA (1) CA2708549C (enExample)
WO (1) WO2009086131A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1698691A1 (en) * 2005-03-04 2006-09-06 Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbH Growth factor mutants with improved biological activity
JP5529754B2 (ja) * 2007-12-21 2014-06-25 ストライカー コーポレイション Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体
AU2010223268B2 (en) * 2009-03-12 2015-04-23 Haase Investments Gmbh Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
CA2785038A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
AU2015202418B2 (en) * 2010-08-20 2017-02-02 Wyeth Llc Designer osteogenic proteins
US9856305B2 (en) 2010-08-20 2018-01-02 Wyeth Llc Designer osteogenic proteins
WO2012023113A2 (en) * 2010-08-20 2012-02-23 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
EP2784083A1 (en) * 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP3171886A4 (en) * 2014-07-21 2018-01-24 The Arizona Board of Regents On Behalf of the University of Arizona Ang-(1-7) derviative oligopeptides and methods for using and producing the same
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN107708416B (zh) * 2015-05-01 2021-06-29 Onl医疗股份有限公司 肽组合物和使用方法
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
PE20200385A1 (es) 2017-04-27 2020-02-24 Lilly Co Eli Variantes de proteina morfogenica osea humana 7 (bmp7)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097825A2 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026713A1 (de) * 2000-05-30 2001-12-06 Walter Sebald Mutein einer Kette eines Proteins aus der Superfamilie des Wachstumsfaktors TGF-beta
JP2008509087A (ja) * 2004-05-27 2008-03-27 アクセルロン ファーマ インコーポレーテッド Ｔｇｆ抑制解除因子およびそれに関連する使用方法
WO2008051526A2 (en) * 2006-10-23 2008-05-02 Stryker Corporation Bone morphogenetic proteins
JP5529754B2 (ja) * 2007-12-21 2014-06-25 ストライカー コーポレイション Ｎｏｇｇｉｎに対する感受性が低下したＢＭＰ変異体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097825A2 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties

Also Published As

Publication number Publication date
EP2222696A1 (en) 2010-09-01
WO2009086131A4 (en) 2009-09-11
US20130184208A1 (en) 2013-07-18
WO2009086131A1 (en) 2009-07-09
US20110039773A1 (en) 2011-02-17
CA2708549C (en) 2014-04-01
JP5529754B2 (ja) 2014-06-25
JP2011507903A (ja) 2011-03-10
AU2008345689A1 (en) 2009-07-09
JP2014121334A (ja) 2014-07-03
CA2708549A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
CA2708549C (en) Bmp mutants with decreased susceptibility to noggin
TWI444475B (zh) 經設計之成骨蛋白類
US20160060319A1 (en) Development of Protein-Based Biotherapeutics That Induced Osteogenesis for Bone Healing Therapy: Cell-Permeable BMP2 and BMP7 Recombinant Proteins (CP-BMP2 & CP-BMP7), Polynucleotides Encoding the Same and Pro-osteogenic Compositions Comprising the Same
JP2008530227A (ja) 骨状態を治療または予防する薬剤組成物
Suh et al. Intracellular delivery of cell-penetrating peptide-transcriptional factor fusion protein and its role in selective osteogenesis
DE69333745T2 (de) Löslicher komplex morphogener proteine und zusammensetzungen davon
WO2008051526A9 (en) Bone morphogenetic proteins
US11008373B2 (en) Designer osteogenic proteins
US20130190236A1 (en) BMP-7 Variants with Reduced Immunogenicity
AU2015202418B2 (en) Designer osteogenic proteins
Dreyer Effect of recombinant mouse sclerostin proteins on bone formation in vitro and in a murine model of sclerosteosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired